<H1>Chapter DOI: 10.1208/aapsj070374<br/>Cited-By Count: 10</H1><table border="1" width="30%"><tr><td>Total References</td><td>112</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>110</td></tr><tr><td>BibStructured Count</td><td width="10%">112</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>86</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>3</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>3</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease.<Emphasis Type="Italic">Toxicol Appl Pharmacol</Emphasis>. 2005;204:355&#8211;360.</td><td><a href=http://dx.doi.org/10.1016/j.taap.2004.08.013>10.1016/j.taap.2004.08.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2003;479:23&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.08.054>10.1016/j.ejphar.2003.08.054</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder.<Emphasis Type="Italic">Lancet</Emphasis>. 1999;354:2132&#8211;2133.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(99)04030-1>10.1016/S0140-6736(99)04030-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Spencer TJ, Biederman J, Madras BK, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter.<Emphasis Type="Italic">Biol Psychiatry</Emphasis>. 2005;57:1293&#8211;1300.</td><td><a href=http://dx.doi.org/10.1016/j.biopsych.2005.03.036>10.1016/j.biopsych.2005.03.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Eriksen JL, Dawson TM, Dickson DW, Petrucelli L. Caught in the act: alpha-synuclein is the culprit in Parkinson&#8217;s disease.<Emphasis Type="Italic">Neuron</Emphasis>. 2003;40:453&#8211;456.</td><td><a href=http://dx.doi.org/10.1016/S0896-6273(03)00684-6>10.1016/S0896-6273(03)00684-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Sidhu A, Wersinger C, Vernier P. Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson&#8217;s disease.<Emphasis Type="Italic">FEBS Lett.</Emphasis> 2004;565:1&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.febslet.2004.03.063>10.1016/j.febslet.2004.03.063</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Dubertret C, Hanoun N, Ades J, Hamon M, Gorwood P. Family-based association study of the 5-HT transporter gene and schizophrenia.<Emphasis Type="Italic">Int J Neuropsychopharmacol</Emphasis>. 2005;8:87&#8211;92.</td><td><a href=http://dx.doi.org/10.1017/S1461145704004948>10.1017/S1461145704004948</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Keikhaee MR, Fadai F, Sargolzaee MR, Javanbakht A, Najmabadi H, Ohadi M. Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder.<Emphasis Type="Italic">Am J Med Genet B Neuropsychiatr Genet</Emphasis>. 2005;135:47&#8211;49.</td><td><a href=http://dx.doi.org/10.1002/ajmg.b.30174>10.1002/ajmg.b.30174</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, ArticleTitle, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Wong DF, Harris JC, Naidu S, et al. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1996;93:5539&#8211;5543.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.11.5539>10.1073/pnas.93.11.5539</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters.<Emphasis Type="Italic">J Neurosci</Emphasis>. 2003;23:4470&#8211;4478.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorders.<Emphasis Type="Italic">Psychiatry Res</Emphasis>. 2004;132:173&#8211;181.</td><td><a href=http://dx.doi.org/10.1016/j.pscychresns.2003.10.004>10.1016/j.pscychresns.2003.10.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Sutcliffe JS, Delahanty RJ, Prasad HC, et al. Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors.<Emphasis Type="Italic">Am J Hum Genet</Emphasis>. 2005;77:265&#8211;279.</td><td><a href=http://dx.doi.org/10.1086/432648>10.1086/432648</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.<Emphasis Type="Italic">Science</Emphasis>. 2003;301:386&#8211;389.</td><td><a href=http://dx.doi.org/10.1126/science.1083968>10.1126/science.1083968</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population.<Emphasis Type="Italic">Neuropsychobiology</Emphasis>. 2004;50:301&#8211;304.</td><td><a href=http://dx.doi.org/10.1159/000080957>10.1159/000080957</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Saier MH Jr. A functional-phylogenetic system for the classification of transport proteins.<Emphasis Type="Italic">J Cell Biochem</Emphasis>. 1999;75:84&#8211;94.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1097-4644(1999)75:32+&lt;84::AID-JCB11&gt;3.0.CO;2-M>10.1002/(SICI)1097-4644(1999)75:32+&lt;84::AID-JCB11&gt;3.0.CO;2-M</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibChapter</td><td>Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith MEA, ed.<Emphasis Type="Italic">Neurotransmitter Transporters: Structure, Function, and Regulation</Emphasis>. Totowa, NJ: Humana Press Inc; 1997;73&#8211;100.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-1-59259-470-2>10.1007/978-1-59259-470-2</a></td><td><b>CrossRef-Meta</b></td>
<td>ChapterTitle, Year</td><td>CrossRef</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Goldberg NR, Beuming T, Soyer OS, Goldstein RA, Weinstein H, Javitch JA. Probing conformational changes in neurotransmitter transporters: a structural context.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2003;479:3&#8211;12.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.08.052>10.1016/j.ejphar.2003.08.052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Chen N, Zhen J, Reith ME. Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2004;89:853&#8211;864.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02386.x>10.1111/j.1471-4159.2004.02386.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1992;89:7782&#8211;7785.</td><td><a href=http://dx.doi.org/10.1073/pnas.89.16.7782>10.1073/pnas.89.16.7782</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RAF. Conserved aspartic acid residues 79 and 113 of the &#946;-adrenergic receptor have different roles in receptor function.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1988;263:10267&#8211;10271.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Wang W, Sonders MS, Ukairo OT, Scott H, Kloetzel MK, Surratt CK. Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2003;64:430&#8211;439.</td><td><a href=http://dx.doi.org/10.1124/mol.64.2.430>10.1124/mol.64.2.430</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2005;314:575&#8211;583.</td><td><a href=http://dx.doi.org/10.1124/jpet.105.085829>10.1124/jpet.105.085829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Barker EL, Moore KR, Rakhshan F, Blakely RD. Transmembrane doamin I contributes to the permeation pathway for serotonin and ions in the serotonin transporter.<Emphasis Type="Italic">J Neurosci</Emphasis>. 1999;19:4705&#8211;4717.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Carroll FI, Lewin AH, Boja JW, Kuhar MJ. Cocaine receptor: biochemical characterization and structure-activity relationships of cacaine analogues at the dopamine transporter.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1992;35:969&#8211;981.</td><td><a href=http://dx.doi.org/10.1021/jm00084a001>10.1021/jm00084a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Madras BK, Pristupa ZB, Niznik HB, et al. Nitrogen-based drugs are not essential for blockade of monoamine transporters.<Emphasis Type="Italic">Synapse</Emphasis>. 1996;24:340&#8211;348.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1098-2396(199612)24:4&lt;340::AID-SYN4&gt;3.0.CO;2-D>10.1002/(SICI)1098-2396(199612)24:4&lt;340::AID-SYN4&gt;3.0.CO;2-D</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Kozikowski AP, Simoni D, Roberti M, et al. Synthesis of 8-oxa analogues of norcocaine endowed with interesting cocaine-like activity.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 1999;9:1831&#8211;1836.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(99)00273-5>10.1016/S0960-894X(99)00273-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Chen N, Vaughan RA, Reigh ME. The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2001;77:1116&#8211;1127.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2001.00312.x>10.1046/j.1471-4159.2001.00312.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Zhen J, Maiti S, Chen N, Dutta AK, Reith ME. Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and aspartate 68 in the human dopamine transporter.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2004;506:17&#8211;26.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2004.10.028>10.1016/j.ejphar.2004.10.028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Lin Z, Wang W, Uhl GR. Dopamine transporter tryptophan mutants highlight candidate dopamine- and cocaine-selective domains.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2000;58:1581&#8211;1592.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:29012&#8211;29018.</td><td><a href=http://dx.doi.org/10.1074/jbc.M011785200>10.1074/jbc.M011785200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Adkins EM, Barker EL, Blakely RD. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2001;59:514&#8211;523.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Barker EL, Perlman MA, Adkins EM, et al. High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1998;273:19459&#8211;19468.</td><td><a href=http://dx.doi.org/10.1074/jbc.273.31.19459>10.1074/jbc.273.31.19459</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Javitch JA, Shi L, Liapakis G. Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors.<Emphasis Type="Italic">Methods Enzymol</Emphasis>. 2002;343:137&#8211;156.</td><td><a href=http://dx.doi.org/10.1016/S0076-6879(02)43131-X>10.1016/S0076-6879(02)43131-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Henry LK, Adkins EM, Han Q, Blakely RD. Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2003;278:37052&#8211;37063.</td><td><a href=http://dx.doi.org/10.1074/jbc.M305514200>10.1074/jbc.M305514200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Ferrer JV, Javitch JA. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1998;95:9238&#8211;9243.</td><td><a href=http://dx.doi.org/10.1073/pnas.95.16.9238>10.1073/pnas.95.16.9238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Gaffaney JD, Vaughan RA. Uptake inhibitors but not substrates induce protease resistance in extracellular loop two of the dopamine transporter.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2004;65:692&#8211;701.</td><td><a href=http://dx.doi.org/10.1124/mol.65.3.692>10.1124/mol.65.3.692</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Lin Z, Wang W, Kopajtic T, Revay RS, Uhl GR. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1999;56:434&#8211;447.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Melamed N, Kanner BI. Transmembrane domains I and II of the gamma-aminobutyric acid transporter GAT-4 contain molecular determinants of substrate specificity.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2004;65:1452&#8211;1461.</td><td><a href=http://dx.doi.org/10.1124/mol.65.6.1452>10.1124/mol.65.6.1452</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Zhou Y, Bennett ER, Kanner BI. The aqueous accessibility the external half of transmem brane domain I of the GABA transporter GAT-1 is modulated by its ligands.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2004;279:13800&#8211;13808.</td><td><a href=http://dx.doi.org/10.1074/jbc.M311579200>10.1074/jbc.M311579200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Wu X, Gu HH. Cocaine affinity decreased by mutations of aromatic residue phenylalanine 105 in the transmembrane domain 2 of dopamine transporter.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2003;63:653&#8211;658.</td><td><a href=http://dx.doi.org/10.1124/mol.63.3.653>10.1124/mol.63.3.653</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Sato Y, Zhang YW, Androutsellis-Theotokis A, Rudnick G. Analysis of transmembrane domain 2 of rat serotonin transporter by cysteine scanning mutagenesis.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2004;279:22926&#8211;22933.</td><td><a href=http://dx.doi.org/10.1074/jbc.M312194200>10.1074/jbc.M312194200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Chen R, Han DD, Gu HH. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2005;94:352&#8211;359.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2005.03199.x>10.1111/j.1471-4159.2005.03199.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Sucic S, Paczkowski FA, Runkel F, Bonisch H, Bryan-Lluka LJ. Functional significance of a highly conserved glutamate residue of the human noradrenaline transporter.<Emphasis Type="Italic">J Neurochem.</Emphasis> 2002;81:344&#8211;354.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2002.00826.x>10.1046/j.1471-4159.2002.00826.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Keshet GI, Bendahan A, Su H, Mager S, Lester HA, Kanner BI. Glutamate-101 is critical for the function of the sodium and chloride-coupled GABA transporter GAT-1.<Emphasis Type="Italic">FEBS Lett.</Emphasis> 1995;371:39&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/0014-5793(95)00859-8>10.1016/0014-5793(95)00859-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Lee SH, Kang SS, Son H, Lee YS. The region of dopamine transporter encompassing the 3rd transmembrane domain is crucial for function.<Emphasis Type="Italic">Biochem Biophys Res Commun.</Emphasis> 1998;246:347&#8211;352.</td><td><a href=http://dx.doi.org/10.1006/bbrc.1998.8618>10.1006/bbrc.1998.8618</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Lee SH, Chang MY, Lee KH, Park BS, Lee YS, Chin HR. Importance of valine at position 152 for the substrate transport and 2beta-carbomethoxy-3beta-(4-fluorophenyl)tropane binding of dopamine transporter.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2000;57:883&#8211;889.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Lin Z, Uhl GR. Dopamine transporter mutants with cocaine resistance and normal dopamine uptake provide targets for cocaine antagonism.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2002;61:885&#8211;891.</td><td><a href=http://dx.doi.org/10.1124/mol.61.4.885>10.1124/mol.61.4.885</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Chen J-G, Sachpatzidis A, Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 1997;272:28321&#8211;28327.</td><td><a href=http://dx.doi.org/10.1074/jbc.272.45.28321>10.1074/jbc.272.45.28321</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Chen J-G, Rudnick G. Permeation and gating residues in serotonin transporter.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2000;97:1044&#8211;1049.</td><td><a href=http://dx.doi.org/10.1073/pnas.97.3.1044>10.1073/pnas.97.3.1044</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Loland CJ, Granas C, Javitch JA, Gether U. Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding.<Emphasis Type="Italic">J Biol Chem.</Emphasis> 2004;279:3228&#8211;3238.</td><td><a href=http://dx.doi.org/10.1074/jbc.M304755200>10.1074/jbc.M304755200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Kristensen AS, Larsen MB, Johnsen LB, Wiborg O. Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants.<Emphasis Type="Italic">Eur J Neurosci.</Emphasis> 2004;19:1513&#8211;1523.</td><td><a href=http://dx.doi.org/10.1111/j.1460-9568.2004.03202.x>10.1111/j.1460-9568.2004.03202.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Mortensen OV, Kristensen AS, Wiborg O. Species-scanning mutagenesis of the serotonin transporter reveals residues essential in selective, high-affinity recognition of antidepressants.<Emphasis Type="Italic">J Neurochem.</Emphasis> 2001;79:237&#8211;247.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2001.00587.x>10.1046/j.1471-4159.2001.00587.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter.<Emphasis Type="Italic">J Neurochem.</Emphasis> 2005;92:21&#8211;28.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02835.x>10.1111/j.1471-4159.2004.02835.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Paczkowski FA, Bryan-Lluka LJ. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.<Emphasis Type="Italic">Brain Res Mol Brain Res.</Emphasis> 2001;97:32&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/S0169-328X(01)00295-9>10.1016/S0169-328X(01)00295-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Kopajtic T, Rucker C, Seidleck BK, Blaschak CJ, Surratt CK. Glycine substitution of selected dopamine transporter (DAT) proline residues predicted for transmembrane domains: effects on dopamine uptake and affinities for cocaine analogs and other DAT ligands.<Emphasis Type="Italic">Soc Neurosci Abs.</Emphasis> 1997;23:408.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Lin Z, Itokawa M, Uhl GR. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression.<Emphasis Type="Italic">FASEB J.</Emphasis> 2000;14:715&#8211;728.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Paczkowski FA, Bryan-Lluka LJ. Role of proline residues in the expression and function of the human noradrenaline transporter.<Emphasis Type="Italic">J Neurochem.</Emphasis> 2004;88:203&#8211;211.</td><td><a href=http://dx.doi.org/10.1111/j.1471-4159.2004.02149.x>10.1111/j.1471-4159.2004.02149.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Williams KA, Deber CM. Proline residues in transmembrane helices: structural or dynamic role?<Emphasis Type="Italic">Biochemistry</Emphasis>. 1991;30:8919&#8211;8923.</td><td><a href=http://dx.doi.org/10.1021/bi00101a001>10.1021/bi00101a001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Brandl CJ, Deber CM. Hypothesis about the function of membrane-buried proline residues in transport proteins.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1986;83:917&#8211;921.</td><td><a href=http://dx.doi.org/10.1073/pnas.83.4.917>10.1073/pnas.83.4.917</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Barlow DJ, Thornton JM. Helix geometry in proteins.<Emphasis Type="Italic">J Mol Biol.</Emphasis> 1988;201:601&#8211;619.</td><td><a href=http://dx.doi.org/10.1016/0022-2836(88)90641-9>10.1016/0022-2836(88)90641-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Li S-C, Goto NK, Williams KA, Deber CM. &#945;-Helical, but not &#946;-sheet, propensity of proline is determined by peptide environment.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1996;93:6676&#8211;6681.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.13.6676>10.1073/pnas.93.13.6676</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Ri Y, Ballesteros JA, Abrams CK, et al. The role of a conserved proline residue in mediating conformational changes associated with voltage gating of Cx32 gap junctions.<Emphasis Type="Italic">Biophys J.</Emphasis> 1999;76:2887&#8211;2898.</td><td><a href=http://dx.doi.org/10.1016/S0006-3495(99)77444-8>10.1016/S0006-3495(99)77444-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Visiers I, Weinstein H, Rudnick G, Stephan MM. A second site rescue mutation partially restores functional expression to the serotonin transporter mutant V382P.<Emphasis Type="Italic">Biochemistry</Emphasis>. 2003;42:6784&#8211;6793.</td><td><a href=http://dx.doi.org/10.1021/bi0273415>10.1021/bi0273415</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Sansom MS, Weinstein H. Hinges, swivels and switches: the role of prolines in signalling via transmembrane alpha-helices.<Emphasis Type="Italic">Trends Pharmacol Sci</Emphasis>. 2000;21:445&#8211;451.</td><td><a href=http://dx.doi.org/10.1016/S0165-6147(00)01553-4>10.1016/S0165-6147(00)01553-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Eisenman G, Dani JA. An introduction to molecular architecture and permeability of ion channels.<Emphasis Type="Italic">Annu Rev Biophys Biophys Chem</Emphasis>. 1987;16:205&#8211;226.</td><td><a href=http://dx.doi.org/10.1146/annurev.bb.16.060187.001225>10.1146/annurev.bb.16.060187.001225</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Sansom MSP. Proline residues in transmembrane helices of channel and transport proteins: a molecular modelling study.<Emphasis Type="Italic">Protein Eng</Emphasis>. 1992;5:53&#8211;60.</td><td><a href=http://dx.doi.org/10.1093/protein/5.1.53>10.1093/protein/5.1.53</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Chen N, Sun L, Reith ME. Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2 alpha-carbomethoxy-3 alpha-(4-fluorophenyl)tropane.<Emphasis Type="Italic">J Neurochem</Emphasis>. 2002;81:1383&#8211;1393.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.2002.00941.x>10.1046/j.1471-4159.2002.00941.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Chen N, Reith ME. Na+ and the substrate permeation pathway in dopamine transporters.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2003;479:213&#8211;221.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.08.070>10.1016/j.ejphar.2003.08.070</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras in involved in selective inhibition by antidepressants and psychomotor stimulants.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1995;48:1030&#8211;1037.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Giros B, Wang Y, Suter S, Mestikawy SE, Pifl C, Caron MG. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1994;269:15985&#8211;15988.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Roubert C, Cox PJ, Bruss M, Hamon M, Bonisch H, Giros B. Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:8254&#8211;8260.</td><td><a href=http://dx.doi.org/10.1074/jbc.M009798200>10.1074/jbc.M009798200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RA. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1989;264:13572&#8211;13578.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Danek Burgess KS, Justice JB Jr. Effects of serine mutations in transmembrane domain 7 of the human an norepinephrine transporter on substrate binding and transport.<Emphasis Type="Italic">J Neurochem</Emphasis>. 1999;73:656&#8211;664.</td><td><a href=http://dx.doi.org/10.1046/j.1471-4159.1999.0730656.x>10.1046/j.1471-4159.1999.0730656.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Penado KM, Rudnick G, Stephan MM. Critical amino acid residues in transmembrane span 7 of the serotonin transporter identified by random mutagenesis.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1998;273:28098&#8211;28106.</td><td><a href=http://dx.doi.org/10.1074/jbc.273.43.28098>10.1074/jbc.273.43.28098</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75</td><td>BibArticle</td><td>Kamdar G, Penado KM, Rudnick G, Stephan MM. Functional role of critical stripe residues in transmembrane span 7 of the serotonin transporter: effects of Na+, Li+, and methanethiosulfonate reagents.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:4038&#8211;4045.</td><td><a href=http://dx.doi.org/10.1074/jbc.M008483200>10.1074/jbc.M008483200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Itokawa M, Lin Z, Cai NS, et al. Dopamine transporter transmembrane domain polar mutants: &#916;G and &#916;&#916;G values implicate regions important for transporter functions.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2000;57:1093&#8211;1103.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Uhl GR, Lin Z. The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions.<Emphasis Type="Italic">Eur J Pharmacol</Emphasis>. 2003;479:71&#8211;82.</td><td><a href=http://dx.doi.org/10.1016/j.ejphar.2003.08.058>10.1016/j.ejphar.2003.08.058</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Sur C, Betz H, Schloss P. A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1997;94:7639&#8211;7644.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.14.7639>10.1073/pnas.94.14.7639</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Barker EL, Kimmel HL, Blakely RD. Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1994;46:799&#8211;807.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Barker EL, Blakely RD. Identification of a single amino acid, Phenylalanine 586, that is responsible for high affinity, interactions of tricyclic antidepressants with the human serotonin transporter.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1996;50:957&#8211;965.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Smicun Y, Campbell SD, Chen MA, Gu H, Rudnick G. The role of external loop regions in serotonin transport: loop scanning mutagenesis of the serotonin transporter external domain.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1999;274:36058&#8211;36064.</td><td><a href=http://dx.doi.org/10.1074/jbc.274.51.36058>10.1074/jbc.274.51.36058</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Norgaard-Nielsen K, Norregaard L, Hastrup H, Javitch JA, Gether U. Zn(2+) site engineering at the oligomeric interface of the dopamine transporter.<Emphasis Type="Italic">FEBS Lett.</Emphasis> 2002;524:87&#8211;91.</td><td><a href=http://dx.doi.org/10.1016/S0014-5793(02)03008-9>10.1016/S0014-5793(02)03008-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Loland CJ, Norregaard L, Gether U. Defining proximity relationships in the tertiary structure of the dopamine transporter: identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1999;274:36928&#8211;36934.</td><td><a href=http://dx.doi.org/10.1074/jbc.274.52.36928>10.1074/jbc.274.52.36928</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1979;208:203&#8211;209.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Khoshbouei H, Sen N, Guptaroy B, et al. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux.<Emphasis Type="Italic">PLoS Biol</Emphasis>. 2004;2:E78.</td><td><a href=http://dx.doi.org/10.1371/journal.pbio.0020078>10.1371/journal.pbio.0020078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Granas C, Ferrer J, Loland CJ, Javitch JA, Gether U. N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2003;278:4990&#8211;5000.</td><td><a href=http://dx.doi.org/10.1074/jbc.M205058200>10.1074/jbc.M205058200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Seidel S, Singer EA, Just H, et al. Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 2005;67:140&#8211;151.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Sucic S, Bryan-Lluka LJ. The role of the conserved GXXXRXG motif in the expression and function of the human norepinephrine transporter.<Emphasis Type="Italic">Brain Res Mol Brain Res</Emphasis>. 2002;108:40&#8211;50.</td><td><a href=http://dx.doi.org/10.1016/S0169-328X(02)00512-0>10.1016/S0169-328X(02)00512-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Loland CJ, Norregaard L, Litman T, Gether U. Generation of an activating Zn(2+) switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2002;99:1683&#8211;1688.</td><td><a href=http://dx.doi.org/10.1073/pnas.032386299>10.1073/pnas.032386299</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Chen N, Rickey J, Berfield JL, Reith ME. Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2004;279:5508&#8211;5519.</td><td><a href=http://dx.doi.org/10.1074/jbc.M306294200>10.1074/jbc.M306294200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Lee FJ, Pristupa ZB, Ciliax BJ, Levey AI, Niznik HB. The dopamine transporter carboxyl-terminal tail; truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1996;271:20885&#8211;20894.</td><td><a href=http://dx.doi.org/10.1074/jbc.271.34.20885>10.1074/jbc.271.34.20885</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Hastrup H, Karlin A, Javitch JA. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2001;98:10055&#8211;10060.</td><td><a href=http://dx.doi.org/10.1073/pnas.181344298>10.1073/pnas.181344298</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Hastrup H, Sen N, Javitch JA. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2003;278:45045&#8211;45048.</td><td><a href=http://dx.doi.org/10.1074/jbc.C300349200>10.1074/jbc.C300349200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Kilic F, Rudnick G. Oligomerization of serotonin transporter and its functional consequences.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2000;97:3106&#8211;3111.</td><td><a href=http://dx.doi.org/10.1073/pnas.060408997>10.1073/pnas.060408997</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Torres GE, Yao WD, Mohn AR, et al. Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1.<Emphasis Type="Italic">Neuron</Emphasis>. 2001;30:121&#8211;134.</td><td><a href=http://dx.doi.org/10.1016/S0896-6273(01)00267-7>10.1016/S0896-6273(01)00267-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Lee KH, Kim MY, Kim DH, Lee YS. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter.<Emphasis Type="Italic">Neurochem Res</Emphasis>. 2004;29:1405&#8211;1409.</td><td><a href=http://dx.doi.org/10.1023/B:NERE.0000026404.08779.43>10.1023/B:NERE.0000026404.08779.43</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Sung U, Apparsundaram S, Galli A, et al. A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2003;23:1697&#8211;1709.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Deken SL, Beckman ML, Boos L, Quick MW. Transport rates of GABA transporters regulation by the N-terminal domain and syntaxin 1A.<Emphasis Type="Italic">Nat Neurosci</Emphasis>. 2000;3:998&#8211;1003.</td><td><a href=http://dx.doi.org/10.1038/79939>10.1038/79939</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Pristupa ZB, Wilson JM, Hoffman BJ, Kish SJ, Niznik HB. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [<Superscript>3</Superscript>H]WIN 35,428 and [<Superscript>3</Superscript>H]GBR 12,935 binding.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1994;45:125&#8211;135.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1999;289:877&#8211;885.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Williams KA, Geldmacher-Kaufer U, Padan E, Schuldiner S, Kuhlbrandt W. Projection structure of NhaA, a secondary transporter from<Emphasis Type="Italic">Escherichia coli</Emphasis>, at 4.0 A resolution.<Emphasis Type="Italic">EMBO J</Emphasis>. 1999;18:3558&#8211;3563.</td><td><a href=http://dx.doi.org/10.1093/emboj/18.13.3558>10.1093/emboj/18.13.3558</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Williams KA. Three-dimensional structure of the ion-coupled transport protein NhaA.<Emphasis Type="Italic">Nature</Emphasis>. 2000;403:112&#8211;115.</td><td><a href=http://dx.doi.org/10.1038/47534>10.1038/47534</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Ravna AW, Sylte I, Dahl SG. Molecular model of the neural dopamine transporter.<Emphasis Type="Italic">J Comput Aided Mol&#8217;Des</Emphasis>. 2003;17:367&#8211;382.</td><td><a href=http://dx.doi.org/10.1023/A:1026116017725>10.1023/A:1026116017725</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Ravna AW, Sylte I, Dahl SG. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;307:34&#8211;41.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.054593>10.1124/jpet.103.054593</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E. Crystal structure of a bacterial homologue of Na<Superscript>+</Superscript>/Cl<Superscript>&#8211;</Superscript> dependent neurotransmitter transporters.<Emphasis Type="Italic">Nature</Emphasis>. 2005;437:215&#8211;223.</td><td><a href=http://dx.doi.org/10.1038/nature03978>10.1038/nature03978</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Lee SH, Chang MY, Jeon DJ, et al. The functional domains of dopamine transporter for cocaine analog, CFT binding.<Emphasis Type="Italic">Exp Mol Med</Emphasis>. 2002;34:90&#8211;94.</td><td><a href=http://dx.doi.org/10.1038/emm.2002.13>10.1038/emm.2002.13</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, VolumeID, FirstPage, Year, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Vaughan RA. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping.<Emphasis Type="Italic">Mol Pharmacol</Emphasis>. 1995;47:956&#8211;964.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR108</td><td>BibArticle</td><td>Vaughan RA, Kuhar MJ. Dopamine transporter ligand binding domains: structural and functional properties revealed by limited proteolysis.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1996;271:21672&#8211;21680.</td><td><a href=http://dx.doi.org/10.1074/jbc.271.35.21672>10.1074/jbc.271.35.21672</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR109</td><td>BibArticle</td><td>Vaughan RA, Agoston GE, Lever JR, Newman AH. Differential binding of tropane-based photoaffinity ligands on the dopamine transporter.<Emphasis Type="Italic">J Neurosci</Emphasis>. 1999;19:630&#8211;636.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Lever JR, Zou MF, Parnas ML, et al. Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible labeling of dopamine transporters: synthesis and covalent binding studies.<Emphasis Type="Italic">Bioconjug Chem</Emphasis>. 2005;16:644&#8211;649.</td><td><a href=http://dx.doi.org/10.1021/bc0497214>10.1021/bc0497214</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>Vaughan RA, Parnas ML, Gaffaney JD, et al. Affinity labeling the dopamine transporter ligand binding site.<Emphasis Type="Italic">J. Neurosci Methods</Emphasis>. 2005;143:33&#8211;40.</td><td><a href=http://dx.doi.org/10.1016/j.jneumeth.2004.09.022>10.1016/j.jneumeth.2004.09.022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Wirtz SE, Parnas L, Jackson TV, et al. Identification of an MFZ 2&#8211;24 photoaffinity labeling site on the human dopamine transporter.<Emphasis Type="Italic">Soc Neurosci Abstr.</Emphasis> 2004;33:53. 19.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>